Market evolution: Medical syringes (CN 90183190) — 2015–2025

Introduction

This report examines the evolution of EU extra-EU trade in non-plastic medical syringes under CN 90183190 — a residual sub-heading that covers syringes made of glass, metal, or other non-plastic materials. This product category sits alongside plastic syringes (CN 90183110) and serves specialised applications in surgery, dentistry, veterinary science, and — increasingly — advanced pharmaceutical delivery such as pre-filled glass syringes for biologics and vaccines.

Over the 2015–2025 period, the EU's trade in this product category underwent a profound transformation. Export value more than doubled (+117%) and export volume tripled (+217%), while import volumes barely grew (+2.6%). The EU's trade balance swung from a deficit of €122.5 million in 2015 to a surplus of €29.5 million in 2025. At the same time, however, domestic production volumes declined by nearly 40% even as production values surged by 161%, pointing to a fundamental restructuring of the EU's non-plastic syringe industry toward higher-value, lower-volume output. The net import reliance indicator rose from −4.8% to +23.3%, signalling growing strategic exposure despite the improved trade balance.

1. Export-Led Growth Reshapes the EU's Trade Position

1.1 EU exports more than doubled in value and tripled in volume

The most striking feature of the 2015–2025 period is the dramatic expansion of EU exports. Export value rose from €317.4 million in 2015 to €689.8 million in 2025 (+117.4%), while export volume surged from 3,309 tonnes to 10,490 tonnes (+217.0%). This implies that the EU massively scaled its outward shipments of non-plastic syringes, more than tripling the physical quantity shipped.

Because volume grew much faster than value, the average export price declined by 31.4% — from €95,883 per tonne to €65,752 per tonne. This price compression likely reflects a combination of increased competition, economies of scale in manufacturing, and a shift in the product mix toward higher-volume but lower-unit-value items being shipped abroad.

1.2 Import growth was moderate in volume but significant in value

By contrast, EU imports followed a very different trajectory. Import volumes edged up only slightly, from 13,065 tonnes to 13,405 tonnes (+2.6%), but import values rose from €439.9 million to €660.3 million (+50.1%). The average import price therefore climbed by 46.3%, from €33,661 per tonne to €49,255 per tonne.

The stagnation of import volumes suggests that the EU's physical demand for non-plastic syringes from outside the bloc did not keep pace with the surge in exports. Rising import prices, meanwhile, point to either supply-side cost increases among trading partners or a shift toward importing higher-value non-plastic syringes.

1.3 The trade balance reversed from a structural deficit to a surplus

Taken together, these divergent dynamics produced a dramatic reversal of the EU's trade balance. In 2015, the EU ran a trade deficit of €122.5 million in this product category, meaning it imported significantly more than it exported. By 2025, this had flipped to a surplus of €29.5 million. At its worst point, the deficit reached €184.3 million. The swing from trough to peak thus amounts to approximately €214 million.

This reversal reflects the EU's transformation from a net buyer to a net seller of non-plastic medical syringes on global markets — a shift driven by the tripling of export volumes rather than by any decline in imports.

2. A Geographic Reconfiguration of EU Trade Flows

2.1 The United States became the EU's dominant export destination

The United States emerged as the EU's largest export market by a wide margin. EU exports to the US grew from €54.3 million in 2015 to €285.4 million in 2025 — an increase of 425.3%. This single bilateral relationship accounts for the largest share of the EU's overall export growth.

Switzerland and China also recorded strong growth, at +197.4% and +185.8% respectively. Meanwhile, exports to the United Kingdom declined by 34.4%, likely reflecting the impact of Brexit and associated trade frictions — a point reinforced by the detection of a significant price shock in UK-bound exports in 2020, with a 98.3% price shift and a high abnormality score of 7.3.

2.2 Import sources diversified, with Switzerland and Taiwan gaining prominence

On the import side, the composition of suppliers shifted substantially. While Mexico and the United States remained important, their relative positions declined (Mexico −27.5%, USA −29.0%). In contrast, two partners saw extraordinary growth:

Switzerland's import value nearly quadrupled, making it the EU's largest single import source by 2025 (€272.5 million). Taiwan's growth was even more dramatic in relative terms: from just €2.1 million to €79.5 million (+3,750%), suggesting the emergence of new manufacturing capacity or trade routing. However, Taiwan's trade relationship exhibited extremely high volatility (CV of 0.91), indicating that this partnership remains relatively unstable.

2.3 Export market concentration increased sharply

One of the most significant structural shifts is the doubling of export concentration. The Herfindahl-Hirschman Index (HHI) for EU exports rose from 1,083 in 2015 to 2,264 in 2025 (+109.1%), moving the EU's export structure from an unconcentrated to a highly concentrated profile (above the 2,500 threshold is typically considered highly concentrated; 2,264 is close).

This rising export concentration is almost entirely explained by the dominance of the US market. With the US absorbing €285 million out of €690 million in total exports (41%), the EU's export profile has become heavily dependent on a single destination. In contrast, the import HHI declined modestly from 2,741 to 2,442 (−10.9%), suggesting a mild diversification of supply sources.

3. Production Restructuring and Rising Strategic Vulnerability

3.1 Domestic production volumes collapsed while values surged

Perhaps the most structurally significant development lies in EU domestic production data. Production volumes fell from 12.45 billion items in 2015 to 7.52 billion items in 2025 (−39.6%), while production values surged from €690 million to €1.8 billion (+160.9%).

The implied unit value of production increased by approximately 333%, indicating a dramatic shift in the product mix. This is consistent with a structural transition away from mass-market non-plastic syringes toward higher-value specialised products — such as glass pre-filled syringes for biologics, insulin pens, and other precision drug-delivery devices. The global demand for glass syringes was further amplified during the COVID-19 vaccination campaign (2021–2023), which required specialised borosilicate glass containers for mRNA vaccines.

3.2 Net import reliance increased despite an improved trade balance

A striking paradox emerges when examining net import reliance. Although the trade balance improved from a €122.5 million deficit to a €29.5 million surplus, the EU's net import reliance rose from −4.8% in 2015 to +23.3% in 2025 — a 588.8% increase.

This apparent contradiction is resolved by the collapse in production volumes. Even though the EU's exports now exceed imports in value terms, the sharp decline in domestic output means that the EU's overall supply of non-plastic syringes has become more dependent on foreign sources relative to what it produces domestically. The trade intensity rose from 68.6% to 88.7%, and export propensity from 53.3% to 76.5%, confirming that the EU's non-plastic syringe sector has become deeply internationalised — a source of opportunity but also of exposure to external shocks.

3.3 Member-state specialisation patterns diverge sharply

The specialisation analysis for 2025 reveals a pronounced divergence among EU member states. France leads with a Revealed Symmetric Comparative Advantage (RSCA) of 0.56 and an RCA of 3.50, indicating strong specialisation. Hungary, Belgium, and Italy also display significant comparative advantages.

At the other end of the spectrum, Portugal (RCA 0.0005), Estonia (0.0007), Slovakia (0.0014), and Luxembourg (0.0017) show virtually no specialisation in this product.

Notably, Italy's export performance stands out at the member-state level: Italian exports surged from €40.4 million to €282.1 million (+597.8%), making Italy the EU's largest exporting member state by value in 2025. Germany also grew strongly (+155.4%), while Denmark saw a remarkable 754.3% increase in imports, suggesting it has become a key entry point for non-EU supply into the EU market.

Conclusion

Over the decade 2015–2025, the EU's trade in non-plastic medical syringes (CN 90183190) was fundamentally reshaped by three intertwined dynamics: a massive expansion of exports (driven primarily by the US market), a restructuring of domestic production toward higher-value output, and a growing strategic vulnerability despite an improved trade balance.

The EU transformed from a net deficit position to a net surplus, but this was achieved through export volume growth rather than through a strengthening of the domestic production base. With production volumes declining by nearly 40% while production values surged by 161%, the EU's non-plastic syringe industry appears to have specialised in premium, high-value-added products — a rational strategic choice, but one that leaves the bloc more exposed to supply disruptions in the lower-to-mid-range segments. The net import reliance figure of +23.3% in 2025, up from −4.8% a decade earlier, underscores this vulnerability.

The geographic concentration of EU exports in the US market (41% of total export value) represents a significant dependency risk, as highlighted by the doubling of the export HHI. Meanwhile, the emergence of Switzerland and Taiwan as major import sources — while diversifying away from Mexico and the US — introduces new bilateral dependencies that warrant monitoring, particularly given Taiwan's extremely high trade volatility (CV of 0.91).

Overall, the EU's non-plastic syringe sector has become more trade-oriented, more specialised, and more productive in value terms — but also more dependent on global markets and more geographically concentrated in its export profile. Policymakers should monitor the tension between the EU's improved trade balance and its rising net import reliance as a signal of underlying structural fragility.